Latest Conference Articles

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final CheckMate 9ER trial results.

Lenvatinib plus belzutifan showed durable activity and a consistent safety profile in advanced clear cell renal cell carcinoma after prior treatment.

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in lenalidomide-refractory multiple myeloma.

Obecabtagene autoleucel improved survival and response durability in B-cell acute lymphoblastic leukemia patients with minimal residual disease–negative remission.

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood cancers, per phase 1 data.

Enfortumab vedotin plus pembrolizumab doubled progression-free survival vs chemotherapy in urothelial cancer.

Datopotamab deruxtecan showed promising activity in advanced urothelial cancer in a phase 1 study.

UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 Genitourinary Cancers Symposium.

A review of 50 studies confirmed the safety and efficacy of radium-223 for metastatic castration-resistant prostate cancer treatment.

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing transplant.

Axatilimab demonstrated consistent response and durability in chronic graft-versus-host disease, regardless of prior treatments, in a phase 1 AGAVE-201 trial analysis.

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

In a retrospective cohort of patients with severe chronic GVHD, combination axatilimab with other GVHD therapies led to clinical benefit.

Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.

Zamtocabtagene autoleucel induced responses, including durable complete responses, in relapsed/refractory diffuse large B-cell lymphoma.

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor activity in patients with relapsed/refractory multiple myeloma.

High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

CTCm from circulating tumor cells correlated with outcomes in mCRPC patients treated with bavdegalutamide in the ARDENT trial.

Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU Cancers Symposium.

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

Darolutamide plus ADT improved outcomes in metastatic hormone-sensitive prostate cancer, regardless of disease volume, in the phase 3 ARANOTE trial.

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for intermediate-risk prostate cancer.

Darolutamide with ADT and docetaxel benefits both younger and older patients with metastatic hormone-sensitive prostate cancer, per post hoc analysis.

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic castration-resistant prostate cancer.

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate cancer, stressing need for improvement.

G-CSF plus docetaxel modification allowed almost all patients with mHSPC to receive an efficacious dose of docetaxel plus darolutamide/ADT.

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic castration-resistant prostate cancer.